Pancreatic Cancer Research

ResearcherArmy Medical UniversityActive in the last 2 years

Haisu Dai

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-1266-2450; OpenAlex author ID A5103045349. Sources: OpenAlex.

Their work

Papers
10 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
17
Papers, trials and grants by year

2016: 1 paper · 2017: 2 papers · 2018: none · 2019: 3 papers · 2020: 1 paper · 2021: 1 paper · 2022: 1 paper · 2023: none · 2024: none · 2025: 1 paper

Papers 10

  1. NPC1L1 on pancreatic adenocarcinoma cell functions as a two-pronged checkpoint against antitumor activity. Co-author DOI 10.1016/j.xinn.2024.100783↗
  2. Pumilio RNA-Binding Family Member 1 Plays a Promoting Role on Pancreatic Cancer Angiogenesis. Co-author DOI 10.1155/2022/9202531↗
  3. PUM1 is upregulated by DNA methylation to suppress antitumor immunity and results in poor prognosis in pancreatic cancer. Co-author DOI 10.21037/tcr-20-3295↗
  4. Human Positive Coactivator 4 Affects the Progression and Prognosis of Pancreatic Ductal Adenocarcinoma via the mTOR/P70s6k Signaling Pathway. Co-author DOI 10.2147/ott.s284219↗
  5. Triptolide enhances TRAIL sensitivity of pancreatic cancer cells by activating autophagy via downregulation of PUM1. Co-author DOI 10.1016/j.phymed.2019.152953↗
  6. PUM1 knockdown prevents tumor progression by activating the PERK/eIF2/ATF4 signaling pathway in pancreatic adenocarcinoma cells. Co-author DOI 10.1038/s41419-019-1839-z↗
  7. ANLN-induced EZH2 upregulation promotes pancreatic cancer progression by mediating miR-218-5p/LASP1 signaling axis. First author DOI 10.1186/s13046-019-1340-7↗
  8. Association of elevated risk of pancreatic cancer in diabetic patients: A systematic review and meta-analysis. Co-author DOI 10.3892/ol.2017.5586↗
  9. MicroRNA-216b-5p Functions as a Tumor-suppressive RNA by Targeting TPT1 in Pancreatic Cancer Cells. Co-author DOI 10.7150/jca.18931↗
  10. Effects of Raf kinase inhibitor protein expression on pancreatic cancer cell growth and motility: an in vivo and in vitro study. Co-author DOI 10.1007/s00432-016-2206-4↗

Closest collaborators

The 17 strongest of 17 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Xingxing Su · 5 shared papers, 2019–2025 · strength 0.69
  2. Yishi Yang · 5 shared papers, 2019–2025 · strength 0.69
  3. Ping Bie · 6 shared papers, 2016–2019 · strength 0.53
  4. Zhiyu Chen · 3 shared papers, 2019–2022 · strength 0.40
  5. Zhiyu Chen · 2 shared papers, 2020–2021 · strength 0.22
  6. Jiaxin Tan · 3 shared papers, 2016–2017 · strength 0.21
  7. Yu You · 3 shared papers, 2016–2017 · strength 0.21
  8. Juanjuan Ou · 1 shared paper, 2025 · strength 0.19
  9. Ruiyang Zi · 1 shared paper, 2025 · strength 0.19
  10. Zhi-Peng Liu · 1 shared paper, 2022 · strength 0.19
  11. Yi Gong · 2 shared papers, 2017–2019 · strength 0.17
  12. Yan Jiang · 1 shared paper, 2020 · strength 0.10
  13. Wei Liu · 1 shared paper, 2019 · strength 0.10
  14. Anbin Wang · 1 shared paper, 2019 · strength 0.10
  15. Jianhua Xu · 1 shared paper, 2017 · strength 0.08
  16. Xuejun Xu · 1 shared paper, 2017 · strength 0.07
  17. Wei Liu · 1 shared paper, 2016 · strength 0.06

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.